Psychopharmacology

The profound effects of climate change on mental health have become increasingly difficult to ignore. 

Bupropion is one of the better tolerated antidepressants, but concerns about anxiety, insomnia, and seizures have dampened its popularity. In this podcast, we’ll see how well those concerns hold up to the evidence.

Substance use disorders are a common comorbidity in individuals with bipolar disorder. Adding cariprazine to their medication regimen may improve symptoms of both disorders.

With a combined 70+ years of clinical experience, the authors discuss scenarios that represent two possible outcomes of discontinuing serotonergic antidepressants.

Two compelling case reports provide additional evidence for potential mechanistic associations between the immune system and schizophrenia.

Antipsychotic drugs are the cornerstone in the management of psychotic disorders, but most patients fail to have a “good” response in short-term trials. Alternative strategies are presented here.

Recent studies and meta-analyses discussed here address mental health hospitalization, optimal treatment, and long-term outcome for children and adolescents with anxiety disorders.

Are mood stabilizers causing strokes? Can we treat bipolar II without medication? The past year brought answers to these questions and more.

Study findings suggest that quetiapine is not a major teratogen, but the risk of malformations must be considered in the context of therapeutic risk-benefit balance.

While many deaths due to opioid overdoses are accidental, there a growing body of evidence that some cases were intentional and that the presence of pain played a role in the decision to end life.

Should hallucinogens such as ketamine, MDMA, psilocybin, and LSD be considered as treatment options for patients with mental illness?

Despite the proven efficacy and safety of medications for ADHD, abuse is a growing concern.

Seven common questions about addiction clinicians regularly hear-as well as the answers.

Recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously thought.

A novel compound holds promise for addressing cognitive deficits in schizophrenia.

An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.

No better time than the summer to digest and reflect on the richness of our field and how we can implement advances in our own work.

A review of systemic medications for dermatologic diseases describes a wide range of adverse events, which range from mild and reversible to permanent and potentially fatal.

The impetus to consider inflammation as potentially relevant to the pathoetiology of domain-based psychopathology (eg, anhedonia) and/or mental disorders, is provided by a confluence of factors discussed here.

The studies reviewed in this article provide a new model for clinical practice-one where the treatment of depressed patients is not governed by trial and error, but rather where patients can access new interventions sooner.

A drug once seen as a widespread danger to society is now experiencing renewed interest as a treatment for medical conditions, including a number of mental health conditions. This brief review explores 5 key issues clinicians can consider when encountering the therapeutic cannabis user.

Make the most of brief psychotherapeutic sessions with these practical tips.

In the elderly, falls are a common and important problem. In the US, fall-related injuries cost approximately $30 billion per year, and about 30% of older adults fall at least once in a given year.

The name of the subspecialty Psychosomatic Medicine has become Consultation-Liaison Psychiatry. And the Academy of Psychosomatic Medicine has changed its name to the Academy of Consultation-Liaison Psychiatry. Here's why.